- Home
- PFO vs ADAG Comparison
PFO vs ADAG Comparison
Compare PFO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFO
- ADAG
- Stock Information
- Founded
- PFO 1991
- ADAG 2011
- Country
- PFO United States
- ADAG China
- Employees
- PFO N/A
- ADAG N/A
- Industry
- PFO Finance Companies
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- PFO Finance
- ADAG Health Care
- Exchange
- PFO Nasdaq
- ADAG Nasdaq
- Market Cap
- PFO 123.7M
- ADAG 100.5M
- IPO Year
- PFO N/A
- ADAG 2021
- Fundamental
- Price
- PFO $9.39
- ADAG $2.20
- Analyst Decision
- PFO
- ADAG Strong Buy
- Analyst Count
- PFO 0
- ADAG 1
- Target Price
- PFO N/A
- ADAG $5.00
- AVG Volume (30 Days)
- PFO 31.8K
- ADAG 89.5K
- Earning Date
- PFO 01-01-0001
- ADAG 07-25-2024
- Dividend Yield
- PFO 6.51%
- ADAG N/A
- EPS Growth
- PFO N/A
- ADAG N/A
- EPS
- PFO N/A
- ADAG N/A
- Revenue
- PFO N/A
- ADAG $815,746.00
- Revenue This Year
- PFO N/A
- ADAG N/A
- Revenue Next Year
- PFO N/A
- ADAG $2.70
- P/E Ratio
- PFO N/A
- ADAG N/A
- Revenue Growth
- PFO N/A
- ADAG N/A
- 52 Week Low
- PFO $6.90
- ADAG $1.30
- 52 Week High
- PFO $8.51
- ADAG $4.38
- Technical
- Relative Strength Index (RSI)
- PFO 58.47
- ADAG 40.41
- Support Level
- PFO $9.33
- ADAG $2.12
- Resistance Level
- PFO $9.49
- ADAG $2.41
- Average True Range (ATR)
- PFO 0.07
- ADAG 0.17
- MACD
- PFO -0.03
- ADAG -0.01
- Stochastic Oscillator
- PFO 19.05
- ADAG 5.22
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end investment company. Its primary investment objective is to produce high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.